乌司他丁联合美罗培南治疗重症肺炎的效果分析

Analysis on the Effect of Ulinastatin Combined with Meropenem in the Treatment of Severe Pneumonia

目的分析乌司他丁联合美罗培南治疗重症肺炎患者的临床效果。方法80例重症肺炎患者随机分为两组。在常规治疗基础上,对照组予以美罗培南治疗,联合给药组予以乌司他丁联合美罗培南治疗。比较两组的疗效、炎性因子、肺功能以及不良反应。结果联合给药组的总有效率显著高于对照组(P<0.05)。治疗后,联合给药组的血清IL-1β、TNF-α水平均显著低于对照组,FEV1、FVC均显著高于对照组(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论乌司他丁联合美罗培南治疗重症肺炎可下调患者的炎性因子水平,改善患者的肺功能,且无明显不良反应。

Objective To analyze the clinical effect of ulinastatin combined with meropenem in the treatment of patients with severe pneumonia.Methods 80 patients with severe pneumonia were randomly divided into two groups.On the basis of conventional treatment,the control group was treated with meropenem,while the combined treatment group was treated with ulinastatin combined with meropenem.The efficacy,inflammatory factors,lung function,and adverse reactions were compared between the two groups.Results The total effective rate of the combined treatment group was significantly higher than that of the control group(P<0.05).After treatment,the levels of serum IL-1β,TNF-αof the combined treatment group were significantly lower than those of the control group,and FEV,and FVC were significantly higher than those of the control group(P<0.05).No statistically significant difference was found in the total incidence of adverse reactions between the two groups(P>0.05).Conclusions Ulinastatin combined with meropenem in the treatment of severe pneumonia can down-regulate the levels of inflammatory factors and improve lung function of patients without obvious adverse reactions.